Drugs / CB06-036
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05828745 | Apr 2024 → Feb 2025 | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06101316 | Sep → Oct 2023 | — | Shanghai Zhimeng Biopharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB06-036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101316 ↗ |
| Route | Oral | “orally taken in the morning” NCT06101316 ↗ |